Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-23-003903

← back to feed
Filed
Feb 8, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Feb 6, 2023 62.77M sh
Current Liabilities Q2 2023 · Dec 31, 2022 $279.29K
Current Liabilities Q2 2023 · Jun 30, 2022 $242.12K
Total Liabilities Q2 2023 · Dec 31, 2022 $279.29K
Total Liabilities Q2 2023 · Jun 30, 2022 $242.12K
Current Assets Q2 2023 · Dec 31, 2022 $76.97K
Current Assets Q2 2023 · Jun 30, 2022 $124.52K
Total Assets Q2 2023 · Dec 31, 2022 $76.97K
Total Assets Q2 2023 · Jun 30, 2022 $124.52K
Operating Cash Flow Q2 2023 · Dec 31, 2021 −$30.1K
Stockholders Equity Q2 2023 · Dec 31, 2021 −$62.43K
Stockholders Equity Q2 2023 · Sep 30, 2021 −$39.99K
Stockholders Equity Q2 2023 · Jun 30, 2021 −$13.78K
Eps Basic Q2 2023 · Dec 31, 2021 −$0.00
Eps Basic Q2 2023 · Dec 31, 2021 −$0.01
Sga Expense Q2 2023 · Dec 31, 2021 $202.06K
Sga Expense Q2 2023 · Dec 31, 2021 $310.96K
Net Income Q2 2023 · Dec 31, 2021 −$220.19K
Net Income Q2 2023 · Dec 31, 2021 −$341.91K
Net Income Q2 2023 · Sep 30, 2021 −$121.71K